Bactiguard today announces its first MDR (Medical Device Regulations 2017/745) product approval following a comprehensive authorization process. The MDR approval relates to the latex BIP Foley Catheter which is an indwelling urinary catheter with Bactiguard’s unique infection prevention technology. Bactiguard’s patented technology is based on...
The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Friday 5 May 2023 at the company’s headoffice in Tullinge, has been appointed. The Nomination Committee for the 2023 AGM in Bactiguard Holding AB (publ) will consist of the following members: Helena Borglund, appointed by TomBact AB Christian...
More licensing projects gives good momentum Third quarter 2022, July - September Revenues amounted to SEK 66.2 (45.2) million, an increase of 46%. Adjusted for currency, revenues increased by 15%. EBITDA amounted to SEK 2.5 (1.2) million, with an EBITDA-margin of 3.8% (2.6). Operating profit/, loss amounted to SEK -11.0 (-10.7) million, a...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday October 27, 2022 at 8:00 CET. In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on October 27. CEO Anders Göransson and CFO Carin Jakobson will present the interim report and answer questions. The...
Continued growth in the licensing business and in our product portfolio Second quarter (April-June 2022) Revenues amounted to SEK 59.9 (46.0) million, an increase of 30%. Adjusted for currency, revenues increased by 13%. EBITDA amounted to SEK -3.8 (1.8) million, with an EBITDA margin of -6.4% (4.0). Operating profit/loss amounted to SEK -14.8...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday July 14, 2022 at 8:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on July 14. CEO Anders Göransson and CFO Carin Jakobson will present the interim report and answer questions. The report and a...
Bactiguard has been informed that the European Patent Office (EPO) intends to grant a European patent for Bactiguard’s infection prevention technology. The new patent, which is the third generation, will provide extensive worldwide protection for the Bactiguard technology until 2039. - We are very pleased that the EPO has confirmed that the new...
The Board of Directors in Bactiguard Holding AB (publ) has been informed by the company’s main owners, Christian Kinch, Thomas von Koch and Jan Ståhlberg, that senior management and key employees in Bactiguard have acquired call options in Bactiguard issued by the three main owners, comprising shares corresponding to 4 per cent of all shares...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 29 April 2022, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2021 and decided that no dividend for the financial year 2021 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...
A broader and stronger licensing business strengthens our position in infection prevention First quarter (January-March 2022) Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7%...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter of 2022 on Wednesday, April 27, 2022, at 08.00 and holds the Annual General Meeting via postal vote on April 29, 2022.In connection with this, an audiocast for shareholders, investors and analysts will be held at 11:00 CET on April 27. CEO Anders...
Bactiguard today entered an agreement to initiate a global development partnership with Dentsply Sirona in the dental field, a new application area for the Bactiguard technology. The initial development phase, which is expected to last approximately one year, can generate USD 0.9 million in development and milestone related revenues for...
The annual report for Bactiguard Holding AB (publ) 2021 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 29 and can be ordered by sending an email to: info@bactiguard.com. This information is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Friday, 29 April 2022. Due to the continued uncertainty about the Covid-19 pandemic, the Board of Directors has decided that the AGM will be conducted without physical...
Bactiguard Holding AB (publ) has appointed Carin Jakobson, who has many years of experience as CFO of listed companies and a background in the medtech and pharmaceutical industry, as Chief Financial Officer. Carin Jakobson, who is currently CFO of the Rolling Optics Group, will take up her new position at Bactiguard in June 2022 and report to...
The hospitals in Ukraine are in urgent need of medical devices to manage the health care challenges related to the outbreak of war. Through a network of doctors at the Karolinska University hospital, supported by the Ukrainian Embassy, Bactiguard is providing intensive care products that Ukrainian healthcare has asked for and need. “It is...
In previous press releases regarding the year-end report for 2021, incorrect information related to "Cash flow from operating activities" has been reported. Correction is made with this press release and the correct PDF is attached for Bactiguard Holding AB's (publ) year-end report 2021. Investments for future sales growth impacted profitability...
Investments for future sales growth impacted profitability Fourth quarter (October-December 2021) Revenues amounted to SEK 46.1 (55.6) million, a decrease of 17%, primarily due to lower license revenue. Adjusted for currency effects revenues decreased by 22%. EBITDA amounted to SEK -12.1 (4.9) million with an EBITDA margin of -26% (9%). Operating...
Bactiguard presents new long-term financial targets in connection with the year-end report for 2021. The new financial targets relate to growth and profitability, with annual revenues of at least 1 billion SEK and annual EBITDA of at least 400 million SEK in 2026. "With Bactiguard's unique technology for infection prevention, scalable business...
Following the announcement of the expanded partnership with Zimmer Biomet, Bactiguard has decided to publish the year-end report for 2021 tonight at 23.00 CET, instead of on Thursday February 10, as earlier announced. An audiocasted presentation will take place on Wednesday February 9 at 15.00 CET. Bactiguard's CEO Anders Göransson and CFO...
Bactiguard and Zimmer Biomet have today agreed to expand the global license partnership, that was initiated in 2019, to cover multiple product segments. The extended exclusive license agreement covers implants for joint reconstruction (hips and knees), sports medicine, craniomaxillofacial and thoracic applications. It includes license and...
The VITAL study, by Professor Pierre Damas and his team, is now published in the well renowned journal Annals of Intensive Care. The study shows a 53% reduction of ventilator-associated pneumonia with Bactiguard’s endotracheal tube. It was presented for the first time at the European Society of Intensive Care congress (ESICM) in October 2021....
“Gabriella is a key person in the company and she has made an impactful contribution to establishing the platform for our continued expansion. While I regret that she has chosen to leave Bactiguard I respect her decision to return to the financial sector. I want to thank her for her significant contributions to the company and wish her all the...
Anders Göransson, Bactiguard's CEO, has acquired shares in Bactiguard Holding AB (publ) corresponding to an amount of SEK 3 million. The investment comprises a total of 17 620 B shares at a share price of SEK 170,28 which corresponds to the average closing price of the stock exchange during the ten preceding trading days. The transaction was made...
The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Friday 29 April 2022 at the company’s headoffice in Tullinge, has been appointed. The Nomination Committee for the 2022 AGM in Bactiguard Holding AB (publ) will consist of the following members: Helena Borglund, appointed by TomBact...
Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. EBITDA amounted to SEK 1.2 (-3.1) million with an EBITDA margin of 3% (-9%). Operating profit amounted to SEK -10.7 (-14.3)...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday October 28, 2021 at 8:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 10:00 CET on October 28. CEO Anders Göransson and CFO Gabriella Björknert Caracciolo will present the interim report and...
This week at the European Society of Intensive Care congress (ESICM), a study from Liège, Belgium on Bactiguard’s endotracheal tubes was presented. The study showed a 53% reduction in ventilator-associated pneumonia (VAP) in intensive care patients, intubated with Bactiguard’s endotracheal tube with subglottic secretion drainage (BIP ETT...
The number of shares and votes in Bactiguard Holding AB has changed due to the recently completed directed share issue. Through the directed share issue, the number of class B shares and votes in Bactiguard has increased by 1,500,000.As of today, the last trading day of the month, the total number of shares in Bactiguard amounts to 35,043,885, of...
The board of directors of Bactiguard Holding AB (publ) (“Bactiguard”) has resolved on a directed new share issue of 1,500,000 B shares at a price of SEK 152 per share, corresponding to approximately SEK 228 million. The Board of Directors of Bactiguard has, based on the authorisation granted by the general meeting on April 28, 2021, resolved...
Aniocyn, Bactiguard's wound care product for pets, is now available at Arken Zoo, Vetzoo and in Musti Group's other stores in Sweden, Norway and Finland. The product cleans and supports the natural wound healing by eliminating both bacteria, viruses and fungi, without irritating or stinging. Musti Group reaches customers via the retail chains...
The Board of Bactiguard Holding AB (publ) has today appointed Anders Göransson as the new CEO. Anders has extensive experience from consulting within McKinsey and has held several senior positions in Amgen, most recently as Head of Innovation Europe. Anders will start his employment in Bactiguard immediately and take up the role of CEO on 1...
Carl Johan Fredin, with many years of international experience from leading companies and positions in pharmaceuticals, MedTech and healthcare, has been recruited to a new role as Chief Licensing Officer. Carl Johan, whose most recent position was with Mölnlycke, will take up his new role on 1 October and report to the CEO. “The interest in...
Bactiguard’s tender award for wound care products for the public sector in Malaysia has been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard’s Wound Care system for infection prevention. “The public sector in Malaysia has consumed almost half...
Major progress in the licensing business and several new partnerships for wound care Second quarter (April-June 2021) Revenues amounted to SEK 46.0 (48.2) million, a decrease of 5%. Adjusted for currencies revenues increased 5%. EBITDA amounted to SEK 1.8 (10.5) million with an EBITDA margin of 4% (22%). Operating profit amounted to SEK -10.0...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday July 15, 2021 at 8:00 CET. In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on July 15. CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo will present the interim report and answer questions. The...
Following successful European regulatory clearance and market launch of Bactiguard-coated Zimmer Biomet trauma implants (ZNN Bactiguard), the initial USD 1 million milestone payment has been released. “I am excited about our partnership with Zimmer Biomet and proud of the progress we have made thus far”, says Cecilia Edström,...
Bactiguard expands its business and launches infection prevention for pets through a collaboration with the Nordic pet retailer Musti Group. The partnership evolves around a new range of wound care products (Aniocyn) for pets. Aniocyn will reach the Musti retail channels in September. “I am excited about entering a completely new market...
The Zimmer Natural Nail (ZNN) Bactiguard implants are now available in Germany, Spain, and the UK, and will be made available to patients and surgeons in other select EMEA (Europe, Middle East and Africa) markets over the summer. “Less than two years from the start of our partnership, we are able to offer the ZNN Bactiguard implants to patients...
Bactiguard and German company Schülke & Mayr GmbH (schülke) have signed an exclusive distribution agreement for Bactiguard’s range of wound care solutions to German hospitals. schülke is one of the leading global manufacturers and distributors within infection prevention and hygiene solutions. The collaboration enables schülke to...
Bactiguard expands its presence in the market for self-care products through a new agreement with another leading Swedish pharmacy chain. The agreement covers both Bactiguard's non-alcoholic disinfection Hydrocyn and a new wound care range. "The agreement with Apotek Hjärtat means that our products will be even more accessible, with more...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April 2021, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2020 and decided that no dividend for the financial year 2020 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...
Continued high activity in the first quarter – infection prevention a global sustainability issue First quarter (January-March 2021) Revenues amounted to SEK 41.8 (48.1) million, a decrease by 13%. Adjusted for currencies the decrease was 3%. EBITDA amounted to SEK 1.9 (14.4) million with an EBITDA-margin of 5% (30%). Operating profit amounted...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter of 2021 on Thursday, April 22, 2021 at 08.00 and holds the Annual General Meeting via postal vote on April 28, 2021. In connection with the interim report, a webcast for shareholders, analysts and media will be held at 11:00 CET on April 22, where CEO Cecilia...
Bactiguard expands its business in the wound care market by partnering with the Spanish company Farmaban S.A. The partnership enables Bactiguard to reach the Spanish market with its full range of products. “We have found a very good match in Farmaban – a partner with significant competence in wound care management and ambition to grow by...
The annual report for Bactiguard Holding AB (publ) 2020 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 28 and can be ordered by sending an email to: info@bactiguard.com. This information is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Wednesday, 28 April 2021. Due to the ongoing pandemic, the Company’s board of directors has decided that the AGM will be conducted without the physical presence of...
A recently published, randomized, controlled multicenter study in India shows that urinary catheters with Bactiguard's coating for infection prevention reduce the risk of catheter-associated urinary tract infections (CAUTI) by 69 % compared to standard catheters. “We are very proud to be able to present such fine results from the largest...
Sweden’s largest pharmacy Apoteket AB will start selling Bactiguard's disinfection solution Hydrocyn® aqua (Hydrocyn) and the products will initially be available via the online store www.apoteket.se. Hydrocyn is a non-alcoholic product that effectively kills virus, bacteria and fungi without irritating the skin. “Apoteket AB has a unique...
Health Canada has approved Bactiguard’s urinary catheter with temperature sensor for infection prevention through an Interim Order. The approval is driven by COVID-19, as Bactiguard’s catheters can reduce the risk of secondary infections for critically ill patients.“Many critically ill COVID-19 patients require a urinary catheter with...
Recovery in the fourth quarter – Infection prevention key in future healthcare Fourth quarter (October-December 2020) Revenues amounted to SEK 55.6 (59.8) million, a decrease by 7% (adjusted for currency -2%). EBITDA amounted to SEK 4.9 (12.2) million with an EBITDA-margin of 9% (20%). Operating profit amounted to SEK -6.4 (1.7) million. Net...
The Nomination Committee of Bactiguard Holding AB (publ) has today held a meeting and decided to propose Thomas von Koch as new Chairman of the Board at the Annual General Meeting on April 28, 2021. The current Chairman of the Board, Christian Kinch, is proposed by the Nomination Committee as new Deputy Chairman of the Board. Cecilia Edström has...
Cecilia Edström has today informed the Board that she wishes to resign as CEO of Bactiguard Holding AB (publ) after seven years in the Executive Management team. The Board will therefore initiate the recruitment of a new CEO. Cecilia Edström will continue in her role as CEO until her successor has been appointed and is available for re-election...
Bactiguard Holding AB (publ) publishes the year-end report for 2020 on Thursday, February 4, 2021 at 8:00 CET.In connection with this, an audiocast for investors, analysts and media will be held at 10:30 CET on February 4. CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo will present the year-end report and answer...
Bactiguard has received an EU grant of SEK 1.4 million for the air bridge that was established for the transport of protective equipment and disinfectants from Asia to Europe in connection with the outbreak of the COVID-19 pandemic. The grant has in full been transferred to Bactiguard's partner Svenskt Industriflyg as compensation for their...
Peter Rådqvist, with many years of international experience from leading companies and positions in MedTech, has been recruited to the role of Global Head of Sales. Peter, whose most recent position was with Straumann, will take up his new position on 1 February and report to the CEO.“Peter Rådqvist has an interesting and broad international...
Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing.“I am very pleased that the CE mark has been secured for Bactiguard-coated Zimmer Biomet trauma implants. This clearance will pave the way for...
Bactiguard continues the launch of the Hydrocyn® aqua (Hydrocyn) product range in Europe by entering a new partnership with Lifecyn S.A. (Lifecyn) in Greece. The collaboration is based on an exclusive distribution agreement for Bactiguard’s Hydrocyn® aqua range, including products for advanced disinfection and wound care. “Launching the...
Bactiguard has received an initial order for coating concentrate from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate license revenues in the fourth quarter 2020 of approximately SEK 9 million. In parallel with the marketing and sales of Bactiguard's BIP Foley...
Bactiguard enters a new partnership with Libera Medica S.L for Spain. The collaboration is based on an exclusive distribution agreement for Bactiguard’s portfolio for infection prevention (BIP), with products for the urinary tract, blood stream and respiratory tract. Libera Medica is a family-owned business, based in Madrid. The company has a...
Weak quarter but the need for infection prevention greater than ever. Third quarter (July-September 2020) Revenues amounted to SEK 34,1 (67,2) million a decreased by 49% (adjusted for currency -46%) due to Covid-19 effects on both license and BIP revenues. In addition, no new license revenue was generated within the quarter while the third...
Bactiguard presents updated financial targets for 2025 in connection with the company's financial report for the third quarter of 2020.Bactiguard's growth strategy for the coming five-year period up to 2025 is based on a continued roll-out of Bactiguard's technology, with a focus on new license agreements and a broader product portfolio. “We are...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 5, 2020 at 8:00 CET. In connection with this, an audiocast for investors, analysts and media will be held at 11:00 CET on November 5. CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo will present the interim report and answer...
The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 28 April 2021 at the company’s headoffice in Botkyrka, has been appoined. The Nomination Committee for the 2021 AGM in Bactiguard Holding AB (publ) will consist of the following members: Helena Borglund, appointed by KK Invest...
Petra Kaur Ljungman, with many years of experience from leading positions in the medical device and pharmaceutical industry, has been recruited for a newly established, global role as Chief Marketing and Communications Officer. She will take up her position in January 2021 and will report to the CEO. “Petra Kaur Ljungman has a broad experience...
Strong growth and earnings development in quarter affected by COVID-19 Second quarter (April-June 2020) Revenues amounted to SEK 48,2 (33,0) million and increased by 46% (adjusted for currency 45%). EBITDA amounted to SEK 10,5 (5,7) million with an EBITDA-margin of 22% (17%). Operating profit amounted to SEK -0,8 (-4,8) million. Net profit/loss...
Health Canada has approved Bactiguard’s endotracheal tubes for infection prevention through an Interim Order. The approval is driven by COVID-19, as Bactiguard’s endotracheal tubes can reduce the risk of secondary infections for critically ill patients. “Many critically ill COVID-19 patients require intubation with an endotracheal tube...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday August 13, 2020 at 7:30 CET.In connection with this, a webcast for investors, analysts and media will be held at 10:00 CET on August 13. CEO Cecilia Edström will present the interim report and answer questions. Bactiguard's new CFO Gabriella Caracciolo...
Bactiguard initiates collaboration with the online pharmacy Apotea on sales of Hydrocyn® aqua (Hydrocyn) to consumers in the Swedish market. Recent tests confirm that Hydrocyn is the first disinfectant on the Swedish market with documentet effect on the new Corona virus causing COVID-19. Sales via Apotea will commence on 5 June. “We are...
The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal...
During May 2020, the number of class B shares in Bactiguard Holding AB (publ) ("Bactiguard") has increased by 241,512. As a result, the total number of shares in the company as of May 29, 2020 amounted to 29,543,885 and the total number of votes to 69,543,885.The increase is a result of the new issue of shares by way of set-off that was approved...
To contribute to the research on COVID-19, Bactiguard donates SEK 120,000 to Karolinska Institutet (KI) at Danderyd Hospital."We have collaborated with Karolinska Institutet at Danderyd Hospital (KI DS) since 2010, where we share lab resources to be able to test how Bactiguard's coating technology interacts with blood. In addition, Bactiguard has...
The development of the Covid-19 pandemic has painfully highlighted the urgent need for infection prevention. This has led to an increased interest in Bactiguard and generated strong sales from mid-March. Total revenues increased by more than 40 percent in the quarter and EBITDA doubled, generating an EBITDA margin of 30 percent and a positive net...
Bactiguard Holding AB (publ) has appointed Gabriella Björknert Caracciolo, currently Head of Strategy, Development and Governance within Transaction Banking, Nordea as new CFO and Executive Vice President. She succeeds Cecilia Edström, who in February was appointed CEO of the company. Gabriella Björknert Caracciolo assumes her new position in...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Wednesday May 13, 2020 at 8:00 CET.In connection with this, a webcast for investors, analysts and media will be held at 10:00 CET on May 13. CEO Cecilia Edström and acting CFO Lina Arverud will present the interim report and answer questions. The report and a...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April, 2020, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2019 and decided that no dividend for the financial year 2019 will be paid. Share premium reserve, retained earnings and the company's loss for the year will be...
The Annual General Meeting will be held on Tuesday, 28 April 2020 at 2:00 pm at the company´s head office at Alfred Nobels Allé 150 in Tullinge. Due to the outbreak of the Covid-19 virus and for the safety of Bactiguard shareholders, the company urges all shareholders not to participate personally, but instead take advantage of the opportunity...
For patients in intensive care, surgery and other conditions where continuous temperature monitoring is important, Bactiguard launches a new urinary catheter – BIP Foley TempSensor. In the same way as other Bactiguard products, BIP Foley TempSensor also prevents infections.“The global Covid-19 pandemic we are now experiencing has painfully...
The annual report for Bactiguard Holding AB (publ) 2019 is now available at www.bactiguard.com The annual report in Swedish is now available as a downloadable PDF document. An English version will be available shortly. A printed version of the report will be available from April 28 and can be ordered by email to: info@bactiguard.se. This...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Tuesday, 28 April 2020 at 2:00 pm at the company´s head office at Alfred Nobels Allé 150 in Tullinge. Registration will commence at 1 pm. Right to participate and notice of...
Bactiguard launched the disinfectant HYDROCYN aqua® in Sweden at the beginning of March and, since then, demand has been high. As late as this weekend, products were flown in from the company's production facility in Malaysia via a newly established air bridge. Now, work is in progress to start production in Sweden as well. “In times like...
The rapid spread of the virus pandemic has led to a large number of countries closing their borders and transport capacity disappearing, as airlines discontinue routes and cancel departures. The effects on the global economy and trade are significant and will lead to uncertain supply of goods and difficulties in increasing delivery capacity for...
Bactiguard Holding AB (publ) ("Bactiguard"), BACTI, has received orders from customers, including the Police Authority, at a total value of over SEK 20 million within the first few days of the launch of HYDROCYN aqua® on the Swedish market. We will initially prioritize customers with critical societal functions and, at the same time, work on...
Bactiguard launches HYDROCYN aqua®, a water-based product that has been proven to have a powerful effect on killing previous variants of coronavirus within 15–30 seconds. Previous experience shows that the proven effect can be transferred to new variants of coronavirus and tests on COVID-19 (SARS-CoV-2) are now underway at the Karolinska...
In the fight against the Corona virus, Bactiguard donates products for infection prevention to Chinese hospitals, at a market value of over 2 million SEK.“To help fight the new corona virus (covid-19) and protect the most severely ill patients, we will donate products from Bactiguard’s and Vigilenz's combined product portfolios to China”,...
Bactiguard Holding AB (publ) (“Bactiguard”) has completed the acquisition of Vigilenz Medical Devices and Vigilenz Medical Supplies (together Vigilenz), which was announced on 4 February 2020.All conditions precedent have been fulfilled and the first part of the total consideration, consisting of a cash payment of USD 4.5 million, has been...
A strong development in fourth quarter earnings, combined with the licensing deal with Zimmer Biomet led to the highest full-year result in Bactiguard's history. The financial effects of both increased BIP sales and new license revenues clearly show that our growth strategy works.Fourth quarter (October-December 2019) Revenues amounted to SEK 61.6...
Christian Kinch today announced to the Board that he will resign as CEO of Bactiguard Holding AB (publ) after close to 16 years. The Board has appointed CFO and Deputy CEO Cecilia Edström as new CEO of Bactiguard and Stefan Grass (CMO) as Deputy CEO. Until a permanent CFO has been recruited, Financial manager Lina Arverud will hold the position...
Bactiguard deepens the partnership that was initiated in 2015 by acquiring Vigilenz Medical Devices and Vigilenz Medical Supplies (together Vigilenz) in Malaysia. The acquisition strengthens Bactiguard’s position in infection control and wound management, as well as innovation and product development capability and capacity. The...
Bactiguard Holding AB (publ) publishes the year end report for 2019 on Wednesday, February 5, 2020 at 8:00 CET.In connection with this, a web conference for investors, analysts and media will be held at 10:00 CET on February 5. CEO Christian Kinch and CFO Cecilia Edström will present the year end report and answer questions. The year end report...
Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.”This is the second order from Well Lead outside the initial contract and further strengthens that end-customer sales in China are picking up. At the...
The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactiguard's technology in a global perspective and a new medical application for long-term...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 7, 2019 at 7:30 CET.In connection with this, a conference call for investors, analysts and media will be held at 11:00 CET on November 7. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report...
The members of the Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 28 April 2020 at the company’s headoffice in Botkyrka, have now been appoined.The Nomination Committee for the 2020 Annual General Meeting in Bactiguard Holding AB (publ) will consist of the following members: Jan...
Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.”The order we have just received from Well Lead is the first outside of the initial contract and therefore an important milestone in our cooperation,...
Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization. “Our...
The product approval for Bactiguard's central venous catheters has been announced by the Mexican Ministry of Health. This provides new opportunities for Bactiguard in providing effective infection prevention for the most vulnerable patients in the second biggest market in Latin America.“We are finally through the registration...
Bactiguard’s indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life. To be able to sell medical devices to the Dutch home care providers...
Stefan Grass with extensive clinical experience as a physician and researcher, combined with senior positions in the pharmaceutical industry, has been recruited to a newly established, global role as Chief Medical and Technology Officer. He will assume his position in October 2019 and report to the CEO.“As a physician and researcher...
The second quarter of 2019 was eventful. We increased our market coverage, secured funding for a very interesting research and development project, broadened the clinical evidence and strengthened executive management. Revenues and earnings were weaker than last year, but one must bear in mind that the second quarter 2018 was very strong.Second...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday August 8, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 8. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report...
A recently published clinical case study conducted at the Central Hospital in Karlstad, Sweden, shows that long-term use of Bactiguard coated Foley (BIP Foley) catheters reduces catheter associated urinary tract infections (CAUTIs) and greatly improves the patient’s quality of life. ”Permanent use of Foley catheters is often associated with...
The Board of Directors has appointed Chief Financial Officer (CFO) Cecilia Edström deputy CEO of Bactiguard, in addition to her current responsibilities.”Cecilia Edström was recruited to Bactiguard ahead of the IPO in 2014 and has had several roles in the company since then. This means that she has acquired a broad and deep...
Bactiguard has partnered with HANSAmed Limited (HANSAmed) to enter the Canadian market. The process to obtain regulatory (MDSAP) approval and Canadian product registration for the BIP portfolio will be financed by HANSAmed and is expected to be completed within 2 years.Canada has a population of 37 million people and the health care system has...
Bactiguard has entered a new partnership with Euromed Swiss AG (Euromed), a leading, specialized Swiss distributor of medical devices. Euromed will be distributing the entire Bactiguard product portfolio for infection prevention in Switzerland."By working with Euromed and their experienced, professional team, we will increase the pace of our...
In collaboration with researchers at Karolinska Institute, Bactiguard has been awarded a research grant of SEK 1.5 million for the development of noble metal-coated stents. The purpose of the project is to reduce the risk of thrombosis in connection with interventions in the bloodstream.“Stents save lives and are used in both acute care and...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 15 May, 2019 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2018 and decided that no dividend for the financial year 2018 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...
A stable beginning of the yearThe beginning of 2019 was stable. Revenues increased somewhat, while the EBITDA result and margin greatly improved. 2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, so we have high expectations for 2019.First quarter (January-March 2019) Revenues amounted to SEK 35.1...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday May 9, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 9. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report and a...
Daniel Lund with many years’ experience in quality, production and supply chain management from the pharmaceutical industry, including AstraZeneca and Pfizer, has been recruited to a new role as Senior Vice President (SVP) Operations. At the same time, Jonas Östregård assumes responsibility for Marketing. Both Daniel and Jonas are...
The annual report for Bactiguard Holding AB (publ) 2018 is now available at www.bactiguard.comThe annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 15 and can be ordered by email to: info@bactiguard.se. This information is information that Bactiguard...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Wednesday, 15 May 2019 at 2:00 pm at the company´s headoffice at Alfred Nobels Allé 150 in Tullinge. Registration will commence at 1 pm. Right to participate and notice of...
The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes to the Annual General Meeting 2019, Professor Anna Martling and Thomas von Koch as new Board members.Anna Martling is Professor of Surgery and Dean of Campus North at Karolinska Institutet and at the same time Senior Consultant Surgeon in cancer at the Karolinska...
2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, primarily strong growth in sales of our own product portfolio for infection prevention (BIP portfolio), the distribution and license agreement with Well Lead for China and the CE mark for orthopaedic trauma implants, which opens possibilities in a...
Bactiguard focuses operations in the Middle East and transfers its distribution to Iraq to a European distributor that, at the same time, takes over accounts receivable at a book value of SEK 17.1 million. The proceeds amount to SEK 12.8 million and, therefore, a write-down of accounts receivable corresponding to the balance of SEK 4.3 million is...
Bactiguard Holding AB (publ) publishes the year end report for 2018 on Thursday, February 7, 2019 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 7. CEO Christian Kinch and CFO Cecilia Edström will present the year end report and answer questions. The year...
Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered before the end of the year and generate revenues in the fourth quarter of approximately SEK 10 million.In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead at an initial value of over 30 million. At...
Bactiguard expands its partnership with Mediplast to include Belgium, the Netherlands and Luxembourg. The previous agreement covered sales and distribution of Bactiguard’s product portfolio for infection prevention (BIP) in Scandinavia. Mediplast now becomes distributor of the BIP portfolio in six European countries.“By teaming up with...
Orthopaedic trauma implants in titanium with Bactiguard's coating for infection prevention have been CE marked and can, from now on, be sold and used in markets that apply EU quality standards. At the same time, the CE-mark opens possibilities for Bactiguard to establish new license agreements covering more markets. The global market for trauma...
Bactiguard was yesterday awarded “Visa vägen-priset” as Employer of the Year. The prize, referred to as Sweden's most important labour market price, is awarded to companies and individuals who lead the way in the labour market by opening opportunities for people with disabilities.The winners of Samhall’s “Visa...
Stable development following a very strong second quarterFollowing a very strong second quarter, the third quarter was a bit calmer, which is natural. Total revenues were somewhat higher than last year primarily due to increased license revenues from our largest partner BD, while BIP sales were lower. It is therefore reassuring that, so far this...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Tuesday November 6, 2018 at 8:00 CET.In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 6. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The...
The product approval for Bactiguard’s urinary (Foley) catheters has been announced by the Egyptian Ministry of Health. This opens new opportunities for Bactiguard in providing effective infection prevention in the most populous country in North Africa and the Middle East.“We are finally through the registration process in Egypt, which...
The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 15 May 2019 at the company’s headoffice in Botkyrka, has been appoined. The Nomination Committee for the 2019 AGM in Bactiguard Holding AB (publ) will consist of the following members: Jan Ståhlberg, Chairman of the...
Bactiguard partners with Mediplast, a medical device company and healthcare supplier in the Nordic region, for sales and distribution in Sweden, Norway and Denmark. By using the Mediplast sales force, the Swedish healthcare providers can be covered more efficiently. At the same time, the collaboration provides a platform for launching the BIP...
In October last year, Bactiguard won a tender for urinary catheters for Sweden’s second largest county, the Västra Götaland region (VGR), but the tender was appealed in other areas than Bactiguard's products. Now the contract is in place, and healthcare providers in both primary and secondary care and 49 municipalities in the region can...
Bactiguard has won a tender for urinary catheters for the Östergötland region in Sweden, which enables healthcare providers in the region to purchase Bactiguard’s urinary catheters for infection prevention in both latex and silicone. The contract is valid for at least 2 years. This agreement gives us the opportunity to increase our...
The main shareholders in Bactiguard Holding AB (publ) broaden the shareholder base and increase the free float in the company's share through a secondary sale of existing shares to three Swedish institutional owners. The transaction comprises 6.63 million B-shares at the price of SEK 39 per share and the total value amounts to SEK 258.6 million....
Bactiguard is launching two line extensions to its BIP Foley Catheter; Female, adapted to the female anatomy and Tiemann, which facilitates catheterization of men. BIP Foley Catheter reduces the risk of catheter associated urinary tract infections, which are common when using indwelling catheters. "The demand for our BIP Foley Catheter is...
The second quarter of 2018 was eventful and financially strong, both revenue and profitability wise. Sales increased by more than 40 percent, driven by more than a doubling in sales of our own product portfolio. We also signed a combined distribution and licensing agreement for China that contributed new licensing revenues. We generated an EBITDA...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Wednesday August 8, 2018 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 8. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report...
Bactiguard has won its first Swedish tender for central venous catheters (CVC), covering the Skåne region. The contract enables hospitals in the region to purchase Bactiguard’s anti-infective central venous catheters (BIP CVC) for at least two years. "The University Hospital in Lund has been using our CVCs for approximately one year with very...
Bactiguard has entered a new partnership with Asid Bonz GmbH (Asid Bonz) through an exclusive distribution agreement for Germany, including all products in Bactiguard's portfolio. “Asid Bonz is an experienced, well respected and professionally managed partner that shares our ambitions to grow in the German market by offering premium products...
Bactiguard takes the next step in China and accelerates its ambitions through a combined distribution and license agreement with Well Lead Medical (Well Lead) with an initial value of more than SEK 30 million. At the same time, the cooperation with the current distributor Jian AN is terminated and Bactiguard pays a compensation of approximately...
Jonas Östregård, who has extensive sales experience from various positions at Astra Zeneca, has been recruited to a new global role as Vice President Sales at Bactiguard. He will join in August 2018 and report to the CEO. ”Jonas Östregård has extensive international sales experience from Europe and Asia. He has spent most of his career in...
At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 16 May, 2018 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2017 and decided that no dividend for the financial year 2017 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...
In 2018, our primary focus is to generate growth through increased sales of our own product portfolio and by developing new licensing businesses, to approach our financial targets, and contribute to saving more lives. Therefore, it is gratifying that we can already report a strong growth in sales of our own product portfolio, which more than...
Bactiguard's licensing partner Smartwise Sweden AB (Smartwise) has signed a strategic collaboration agreement with AstraZeneca regarding, among other things, the development of advanced vascular injection catheters with Bactiguard coating for new, innovative treatment methods of cardiovascular disease and cancer. ”The collaboration agreement...
Bactiguard signs distribution agreement for Mexico with Degasa, a well-established family owned company in the second largest market in Latin America. “Degasa is a strong distributor in the attractive Mexican market, with both the resources and competence required to drive a successful market introduction”, says Christian Kinch, CEO at...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Tuesday May 8, 2018 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 8. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The report and a...
The annual report for Bactiguard Holding AB (publ) 2017 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 11 and can be ordered at info@bactiguard.se. This information is information that Bactiguard Holding AB...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Wednesday, 16 May 2018 at 2:00 PM at the company´s headoffice at Alfred Nobels Allé 150 in Tullinge. Registration wlll commence at 1 pm. Right to participate and notice of...
Mikael Ymer, one of Sweden's most talented and promising tennis players, returns to Good to Great Tennis Academy and Team Bactiguard. He climbs the world rankings and is now among the top 350 players in the world, while preparing to play the next Davis Cup-match for Sweden. Mikael Ymer, together with his older brother Elias Ymer, Daniel Windahl,...
Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in March and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...
Bactiguard is launching a line extension to its BIP CVC with the popular Raulerson syringe for easier handling and insertion. BIP CVC is shown to reduce the risk of costly blood stream infections, which are common following the use of central venous catheters. "The demand for our BIP CVC is steadily increasing, and we are happy that we...
Bactiguard has entered a distribution agreement for Belgium and the Netherlands with Ecomed Services NV (“Ecomed”), a leading provider of innovations in infection control in the Benelux countries. “Ecomed is a specialized distributor of medical devices to the public and private hospitals in Belgium and the Netherlands. They grow their...
In 2017 Bactiguard signed a framework agreement with Region Skåne, which enables both county councils and municipalities to order Bactiguard's infection prevention urinary catheters. The initial contract expires on April 30th, 2018 and now Region Skåne chooses to extend the agreement for another year until April 30th, 2019. "The demand...
2017 was a good year for Bactiguard. Our objective was to generate growth, with sustained cost control, to approach our long-term financial targets of 20 percent growth and an EBITDA margin of 30 percent. It is therefore gratifying that sales for the full year amounted to close to MSEK 154, which means growth of 20 percent, quite in line with our...
Bactiguard Holding AB (publ) publishes the year end report for 2017 on Tuesday, February 6, 2018 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 6. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The year end report...
The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes that the Annual General Meeting 2018 elects Jan Ståhlberg as new member and Chairman of the Board, as Stanley Brodén who has been the Chairman of the Board since 2015 has declined reelection. Jan Ståhlberg is Vice Chairman of EQT AB and has been active in EQT since...
Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in December and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...
The product approval for Bactiguard's endotracheal tubes has been announced by the Indian Ministry of Health & Family Welfare. This means that Bactiguard can offer its complete portfolio of products for effective and safe infection prevention in one of the largest and fastest growing markets in the world. The Central Drugs Standard Control...
The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Wednesday 16 May, 2018 in Botkyrka. In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of four members. The chairman of the Board of Directors shall contact the three largest...
A recently published clinical study* conducted at the Karolinska University Hospital in Sweden shows that Bactiguard’s infection prevention central venous catheter – BIP CVC had significantly fewer adverse events compared to a standard uncoated CVC. The study also shows that Bactiguard's noble metal alloy does not expose patients or the...
We can now put eight quarters of rising sales based on rolling twelve-month figures behind us, which is very positive. This means that more and more patients have access to effective and safe infection prevention, not least in Sweden where we have recently won another tender. The value of delivered products increased by close to 50% in the...
Bactiguard has received a commitment for a three-year credit facility of SEK 180 million from Skandinaviska Enskilda Banken (SEB), in the form of an overdraft facility of SEK 30 million and a term loan of SEK 150 million. The credit facility replaces current bank financing as well as a loan from the company's main shareholders. "For some time,...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday, November 9, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 9. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The...
Bactiguard has entered a partnership with Neon Laboratories Limited (“Neon”) for the north, west and east zones of India, covering a majority of the Indian population. The Neon Group is a family-owned, manufacturer and distributor of pharmaceuticals and medical devices, with a turnover of more than 85 MUSD. The company started operations in...
Bactiguard has won a tender for urinary catheters for the Västra Götaland region (VGR) in Sweden, which enables healthcare providers in both primary and secondary care and 49 municipalities in the region to purchase Bactiguards’ urinary catheters for infection prevention. The contract is valid for 2 years and can be extended for another 2...
The Hong Kong product approval for Bactiguard's central venous catheters for infection prevention has been announced by the Medical Device Control Office. Hong Kong is a small, but strategically important market, as it serves as a reference for new approvals and market acceptance in neighbouring China. The Medical Device Control Office in Hong...
Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in September and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention,...
The product approval for Bactiguard's central venous catheters has been announced by the Indian Ministry of Health & Family Welfare. This provides new opportunities for Bactiguard in providing effective infection prevention in one of the largest and fastest growing markets in the world. The Central Drugs Standard Control Organisation...
Bactiguard Holding AB (publ) has appointed Cecilia Edström, today Senior Vice President Sales and New Business, as acting Chief Financial Officer (CFO). She succeeds Fredrik Järrsten, who will leave Bactiguard to assume a new CFO role in another company. Cecilia Edström will assume her new position on 15 September. ”Fredrik Järrsten has...
Bactiguard saves lives by preventing healthcare associated infections. With the development in the second quarter, sales of our own product portfolio have now increased for seven consecutive quarters, based on rolling twelve-month figures. This means that more patients have access to effective and safe infection prevention. The value of delivered...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday, August 10, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 10. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...
Good to Great Tennis Academy and Swedish medtech company Bactiguard AB have today announced that they are continuing to strengthen the development of future tennis talent in Sweden by focusing on younger players between 13 to 14 years of age. Together, Good to Great Tennis Academy and Bactiguard have created a new Team Bactiguard consisting of...
Bactiguard has received a third major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention, which will be delivered in June and generate revenues of some 3 million SEK. We have received a third major order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters...
Bactiguard has won a tender for urinary catheters for the southern region (Region Skåne) in Sweden, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters from 1 August 2017. The contract initially runs until 30 April 2018 and can be extended on an annual basis until 30...
Bactiguard has entered partnership with Surgical Innovations Pty Ltd (“SI”), a company within the Medical arm of Ascendis Health, the JNB listed healthcare giant and leading supplier to the healthcare sector in South Africa. “Surgical Innovations is a leading provider of medical devices to both public and private hospitals, representing...
Bactiguard has entered partnership with Gada Italia Srl (“Gada”), a specialized and leading distributor of medical devices and integrated healthcare services. “The Gada group is a leading provider of integrated healthcare solutions to the public and private hospitals in Italy and we are confident that they have the competence and...
Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years. "The Stockholm county council is Sweden’s largest region...
At Bactiguard Holding AB’s (publ) Annual General Meeting on May 18, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2016. It was decided that no dividend for the financial year 2016 will be paid and that the company's loss (for the year) will be carried forward. The Board of...
Strong financial start in 2017. Revenue grew 58 % in the first quarter and we reached an EBITDA margin of 33 %. The reason for the improved results, besides a new licensing deal, is that we have higher revenues from C.R. Bard and continued cost control. The volume of products sold from our own portfolio is lower than last year, but the product...
Bactiguard signs distribution agreement and enters partnership with Biodina for Brazil. “Biodina has a very strong track record of successfully introducing new and advanced products on the Brazlian market and we are very happy to have them as our partner. We have not been satisfied with the development of Bactiguard sales in Brazil and we...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday, May 4, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 4. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
The annual report for Bactiguard Holding AB (publ) 2016 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 5 and can be ordered at info@bactiguard.se. This information is information that Bactiguard Holding AB...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”) are hereby given notice to attend the Annual General Meeting to be held on Thursday, 18 May 2017 at 2:00 PM at the company´s office at Alfred Nobels Allé 150 in Tullinge. Registration commences at 1 PM. Right to participate and notice of intent to...
Bactiguard has won a tender for urinary catheters covering the Swedish county Kalmar. The contract is an extension of the previous agreement, lasts for 4 years and enables healthcare providers to purchase Bactiguards’ anti-infective urinary catheters. "The Kalmar region has been using our products for the last 2 years and recently decided to...
A recent, independent clinical study conducted in Hong Kong confirms that Bactiguard-coated Foley catheters reduce symptomatic catheter associated urinary tract infections and that the effect is even more pronounced among long-term users. ”Given our recent market entry into China and Hong Kong we are pleased that the study confirms previously...
In many ways, 2016 was a good year for Bactiguard. We exceeded our goal of doubling the volume of products sold in our own portfolio by a wide margin and delivered approx. 418,000 units. We made a breakthrough in China and India, now our two largest markets, and we entered several European markets, while advancing our position in the domestic...
Bactiguard and Smartwise Sweden AB (Smartwise) have entered into a joint development project for advanced, Bactiguard-coated vascular injection catheters. At the same time, a license agreement has been signed. Smartwise will pay USD 2.5 million, for the exclusive and global right to the Bactiguard technology for this application, payable in...
Bactiguard Holding AB (publ) publishes the year end report for 2016 on Thursday, February 9, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 9. CEO Christian Kinch and CFO Fredrik Järrsten will present the report and answer questions. The year end...
Bactiguard signs distribution agreement and enters partnership with Heal Pharma for Egypt. The product registration has been initiated and market launch is planned for the second quarter of 2017. “Egypt is the most populous country in the Arab world, with major challenges in the healthcare sector. We are convinced that...
Bactiguard has entered into partnership with Roeser Medical GmbH (“Roeser”) and signed an exclusive distribution agreement for Germany and Switzerland. At the same time, an order for products worth some EUR 400 000 has been placed and will be delivered throughout 2017. Bactiguard’s central European coverage has expanded significantly in...
Bactiguard outstanding bond loan was repaid in full on 12 December. The refinancing solution consists of loans totaling SEK 150 million. The bond loan Bactiguard issued in December 2011, with an initial nominal value of SEK 450 million, an annual interest rate of 11% and a duration of 5 years, matured on 12 December. The outstanding...
The call option program established by the main shareholders and aimed at key individuals in Bactiguard, matured on 30 November 2016. During the exercise period, a total of 688 000 B shares were acquired, corresponding to 2.07 percent of the capital and 0.99 percent of the votes, reducing the holdings of the main shareholders accordingly....
The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Thursday, 18 May 2017 in Botkyrka. At the Annual General Meeting (AGM) in 2016, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall consist of four members. The chairman of the Board of Directors shall contact the three largest...
In the third quarter we report a continued positive trend in sales of our own portfolio of infection prevention products for the healthcare sector. We have delivered a total of approx. 284,000 products so far this year, an increase by approx. 260 percent. This means that we are already now close to our goal of at least doubling the...
In order to maintain financial flexibility after the repayment of the bond, and until a long-term financing solution is in place, the main shareholders of Bactiguard have issued a loan commitment of up to SEK 50 million Bactiguard has previously announced that it has secured the refinancing of the bond loan maturing December 12, 2016 through the...
Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday, November 10, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 10. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...
Bactiguard has received a new major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention We have received a new major order from our distributor in China, Jian An Pharmaceuticals. The order is for 100,000 BIP Foley catheters, which is the same quantity as the initial order received in early 2016. The order will...
Bactiguard expands its European presence in four new markets, by entering partnerships with Sanova Pharma for Austria, Pofam-Poznaǹ for Poland, Mediq Suomi for Finland and Inex Medical for Greece. “We are confident that combining Bactiguard’s portfolio for infection prevention, with the local expertise and reach of our partners, both in...
Bactiguard announces the launch of its new BIP Endotracheal Tube Evac, for prevention of ventilator associated pneumonia (VAP). It is one of a kind and designed to offer the best infection protection available on the market. VAP is the second most common nosocomial infection in the ICU, and associated with high-risk pathogens such as MRSA,...
A recent independent and randomized clinical study confirms that Bactiguard-coated Foley catheters reduce catheter associated urinary tract infections in ICU patients. The study was conducted at the King Fahad Hospital in Saudi Arabia and included 60 patients in the Intensive Care Unit (ICU), who were catheterized for at least 3...
Bactiguard has won a tender for urinary catheters covering the two Swedish counties Kronoberg and Blekinge. The contract is an extension of the previous agreement for 2 (+2)years which enable healthcare providers to purchase Bactiguard anti-infective urinary catheters. "This specific region has been using our products since 2012 and has now...
Bactiguard starts a new clinical trial that aims to reduce the risk of catheter associated urinary tract infections and the use of antibiotics in patients undergoing prostate cancer surgery in the well renowned Martini-Klinik of the University Medical Center Hamburg-Eppendorf. “In our never ending quest to improve the quality of life for our...
The positive trend with increased sales of our own portfolio of infection prevention products for the healthcare sector has continued and we delivered almost 110 000 units in the quarter. We have delivered a total of approximately 200 000 products so far this year, well above the total annual volume for 2015. License revenues are also back...
Bactiguard has received a new order from India of some 60 000 Foley catheters for infection prevention. The initial order from India, which was received in December 2015, consisted of some 50 000 Foley catheters for infection prevention (BIP Foleys). The new order consists of some 60 000 BIP Foleys and will generate direct sales...
The maturity of the credit facility of SEK 100 million that Bactiguard received as a loan commitment in November 2015, has been extended until 31 December, 2017 In November 2015 Bactiguard entered a credit facility agreement of SEK 130 million, consisting of a loan commitment of SEK 100 million and a renewal of bank overdraft facility of SEK 30...
Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday, August 11, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 11. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...
The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares. The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares. Other members of senior management have also been offered the...
At Bactiguard Holding AB’s (publ) Annual General Meeting on May 19, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2015. It was decided that no dividend for the financial year 2015 will be paid and that the company's loss (for the year) will be carried forward....
Bactiguard started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments...
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday, May 12, 2016 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 12. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and...
Repeated infections and subsequent antibiotic treatments are a painful part of daily life for patients with spinal cord injury, who use urinary catheters. Bactiguard and the Centre for Spinal Cord Injury are now starting a new clinical trial, which aims to increase the quality of life for these patients. “We are excited about the study and...
Bactiguard and BioInteractions have received a European research grant aimed at developing a new generation of vascular access catheters, with new bio-smart materials for medical devices. The technology will be developed in a joint project with BioInteractions, UK and Bactiguard, financed by VINNOVA and Innovate UK. Some of the most serious...
The annual report for Bactiguard Holding AB (publ) 2015 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 10 and can be ordered at info@bactiguard.se. This is information that Bactiguard Holding AB (publ) is...
The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Thursday, 19 May 2016 at 2:00 PM at the company´s office at Alfred Nobels Allé 150 in Tullinge. Registration commences at 1 PM. Right to participate and notice of intent to...
Bactiguard is exhibiting at Europe´s biggest annual congress for doctors specialized in urology, the European Association of Urology (EAU) Congress in Munich on March 11 – 14. Bactiguard’s infection prevention solution can be found in hall B, at booth number A03. Europe is one of our markets in focus and the EAU Congress offers a great...
2015 ended with the long-awaited product approval in China and a first order from India. As a result of large deliveries in the fourth quarter we doubled the total volume of units shipped, compared with the year before. An additional order from C.R. Bard generated additional revenue and strengthened the result. A new licensing deal opened...
Bactiguard Holding AB publishes the year end report for 2015 on Thursday February 18 at 08:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 18. CEO Christian Kinch and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available...
A laboratory study, recently published in the Journal of Biomedical Material, by scientists at Karolinska Institutet and Bactiguard, shows that Bactiguard’s coating can reduce the risk of a thrombosis. A previous clinical study shows that Bactiguard’s Infection Protection central venous catheters reduce the number of bloodstream infections by...
Following the Chinese approval of Bactiguard’s Foley catheters for infection prevention, which was recently announced, the company has received an initial order of 100,000 catheters. In January 2016, the doors were opened to China, one of the largest and fastest growing markets in the world, with the approval of the company's Foley catheter...
In January, Bactiguard exhibited for the first time at the Conference of Urological Society of India together with its Indian distributor Biorad Medisys Pvt Ltd. The congress was an important step in launching Bactiguard’s Infection Protection products in the Indian market. The annual Conference of Urological Society of India (USICON), arranged...
The product approval for Bactiguard's foley catheters for infection prevention in China, has now been announced by China Food and Drug Administration (CFDA). This opens the door to one of the largest and fastest growing markets in the world. ”Finally a breakthrough for Bactiguard in China. We started the approval process with CFDA already in...
In August 2015, Bactiguard received a one off order from C.R. Bard (Bard), intended to increase their safety stock, which generated additional sales of approximately 28 MSEK in the third quarter. Bard has subsequently revised their need of safety stock. This adjustment will have a negative impact on Bactiguard’s revenues of approximately 8...
For the ninth year in a row Bactiguard is exhibiting at Arab Health, which is one of the world's largest conferences for the health care sector. The interest in preventive and anti-infective solutions for healthcare associated infections are growing explosively along with the global threat of multiresistant bacteria and antibiotic resistance....
Attorney Jan Lombach will replace Christian Kinch and has also been appointed chairman of the Nomination Committee. Following these changes, the Nomination Committee for the 2016 AGM in Bactiguard Holding AB (publ) will consists of the following members: Stanley Brodén, Chairman of the Board of Directors Jan Lombach, appointed by KK Invest AB,...
The planned multi-center clinical study in India has been initiated and the first patients recruited at two reputable hospitals. The purpose of the study is to further validate the efficiency and patient safety of Bactiguard’s Foley catheters in the prevention of catheter-related urinary tract infections. Healthcare associated infections are a...
Bactiguard has received a major order from India of some 50 000 Foleys for infection prevention. At the same time, the planned clinical study has been initiated. The first order from India consists of some 50 000 Foley catheters for infection protection (BIP Foleys) and generates direct sales revenues of close to 2 million SEK, at product...
Bactiguard has received an order from the Middle East, comprising 2 000 central venous catheters (BIP CVC) and 20 000 Foleys (BIP Foley). The delivery will take place before the end of the year. The Middle East is one of Bactiguard’s focus markets and continues to generate repeat orders, so far primarily of Foley catheters. There is a growing...
The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 19 May, 2016 in Botkyrka. At the Annual General Meeting (AGM) in 2015, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall consist of four members. The chairman of the Board of Directors shall contact the three largest shareholders...
Third Quarter (July-September 2015) Revenues amounted to SEK 61.4 (28.1) million. The increase (118 %) compared to the corresponding quarter 2014 is mainly attributable to the additional order from C.R. Bard. EBITDA amounted to SEK 33.9 (2.2) million. Operating profit amounted to SEK 25.7 (-5.3) million. Reported net profit for the quarter...
Bactiguard and Vigilenz Medical Devices (Vigilenz), a Malaysian supplier of medical and surgical products, have entered into a license agreement for Bactiguard coated orthopaedic implants, covering the Asean region. Bactiguard aims to expand its licensing business to new therapeutic areas and Vigilenz’ ambition is to enhance its existing...
Bactiguard has entered a credit facility agreement of 130 million SEK in total. Combined with the company’s cash position, the credit facility secures the refinancing of Bactiguard’s bond loan, which matures in December 2016. During the autumn, Bactiguard has been working on securing the refinancing of its bond loan. The income received in...
Bactiguard Holding AB publishes the interim report for the third quarter on Thursday 12 November at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 12. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Ulrika Berglund has been appointed Head of External Affairs at Bactiguard and will be responsible for communications and public affairs. She succeeds Cecilia Edström, who will assume an extended responsibility for sales and business development. “I am very pleased with the recruitment of Ulrika Berglund to Bactiguard. With her extensive media...
Two recent clinical studies, both independent and randomized, show that Bactiguard-coated Foley catheters and endotracheal tubes reduce catheter associated urinary tract infections and ventilator associated pneumonia. The first study was conducted in Spain and included 116 patients catheterized for 2 – 14 days, with a mean of 4 days, during the...
Second Quarter (April-June 2015) During the second quarter, a total of approx. 58,000 (44,000) BIP products were delivered. Revenues amounted to SEK 27.7 (31.2) million. EBITDA amounted to SEK -10.0 (2.2) million. Provisions for severance pay to the former CEO as well as for doubtful accounts receivable have negatively affected EBITDA during the...
Bactiguard has received a major, one off order from C.R. Bard (Bard) intended to increase their safety stock of Bactiguard-coated Foleys for infection control. The order will generate additional sales for Bactiguard of approximately 28 MSEK in the third quarter and make a positive contribution to cash flow. The additional order will lead to...
Bactiguard Holding AB publishes the interim report for the second quarter on Thursday 13 August at 8:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 13. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Bactiguard delivers an order of more than 20 000 Foley catheters for infection control to Saudi Arabia. At the end of June, Bactiguard delivered an order of more than 20 000 Foley catheters to Gulf Medical in Saudi Arabia. Gulf Medical distributes Bactiguard’s portfolio of products for infection control to the healthcare system in both Saudia...
Niels Christiansen leaves his position as CEO of Bactiguard Holding AB (publ) with immediate effect. The Board has appointed Christian Kinch, currently Chairman of the Board, as new CEO. Stanley Brodén has been appointed Chairman of the Board until the Annual General Meeting (AGM) in 2016. “The recruitment of Niels Christiansen as CEO was...
At Bactiguard Holding AB’s (publ) Annual General Meeting on May 21, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2014. It was decided that no dividend for the financial year 2014 will be paid and that the company's loss (for the year) will be carried forward. The Board of...
First quarter (January-March 2015) Revenues amounted to SEK 28.8 (34.5) million EBITDA amounted to SEK -26.8 (9.8) million. A changed market strategy for Russia and India has led to provisions for doubtful receivables. These provisions, together with non-recurring costs attributable to a strategic marketing project, have negatively affected EBITDA...
Bactiguard Holding AB publishes the interim report for the first quarter on Tuesday 12 May at 8:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 12. CEO Niels Christiansen and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Bactiguard has entered an exclusive distribution agreement for Israel with Dover Medical & Scientific Equipment Ltd. The agreement covers sales of all products in the Bactiguard Infection Protection portfolio. “Changing our market strategy for Israel from direct sales to sales via a distributor is a more cost efficient way of expanding...
Bactiguard delivers an order of some 20 000 products for infection control to Southern Africa, comprising both Foley and central venous catheters for the healthcare system in Angola. In July 2014, Bactiguard expanded its market presence to seven countries in Sub-Saharan Africa and made an initial delivery of Foley catheters to Zambia. The...
The annual general meeting of Bactiguard Holding AB (publ), (“Bactiguard”), will be held on Thursday, 21 May 2015 at 2:00 pm at Vasagatan 7 in Stockholm, in the Vasa Hall. Registration commences at 1:00pm and coffee will be served before the meeting. Shareholders right to participate and notification Shareholders wishing to participate at...
The annual report for Bactiguard Holding AB (publ) 2014 is now available at www.bactiguard.com The annual report is available in both a Swedish and English online version and as a downloadable PDF document. A printed version of the report will be available from 6 May and can be ordered at info@bactiguard.se. This is information that Bactiguard...
Bactiguard has terminated the distribution agreement for Russia and evaluates an alternative sales strategy for India. In connection with the above, the company has decided to make reservations in the interim results for the first quarter of 2015 for doubtful receivables, with a negative effect on results of approximately MSEK 24. During the...
Bactiguard expands in Europe by entering an exclusive distribution agreement for Switzerland, covering all products in the Bactiguard Infection Protection portfolio. “We are delighted about our expansion in Switzerland, a market recognized for its high quality healthcare. We have managed to break into one of Europe's toughest markets, which...
Fourth quarter (October-December 2014) Revenues amounted to SEK 25.1 (47.9) million EBITDA amounted to SEK -3.9 (25.2) million Reported net profit for the quarter amounted to SEK -15.7 (18.9) million, corresponding to SEK -0.47 (0.95) per share. Net profit for the quarter has been negatively affected by market valuation of the bond with SEK -1.1...
Bactiguard Holding AB publishes the year end report for 2014 on Thursday 19 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on February 19. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available at...
The Board of Directors has appointed Niels Christiansen as the new CEO of Bactiguard. Niels Christiansen has extensive management experience from various positions in the medical device, life science and energy sectors, most recently as the CEO of HemoCue AB. He will assume his new position in Bactiguard on March 16. At that time, Johan Rugfelt...
The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 21 May, 2015 in Stockholm. At the Annual General Meeting (AGM) in 2014, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall be formed in a process where the Chairman of the Board contacts the three largest shareholders, based on...
Third quarter (July-September 2014) Revenues amounted to SEK 28.1 (32.5) million, a decrease of 14 % over the corresponding quarter last year EBITDA amounted to SEK 2.2 (4.7) million, a decrease of 53 % over the corresponding quarter last year Reported net profit for the quarter amounted to SEK -15.7 (-5.1) million, corresponding to SEK -0.47...
Bactiguard Holding AB publishes the interim report for the third quarter on Friday 14 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on November 14. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...
Bactiguard strengthens its sales and marketing organization by recruiting Nina Nilsson as Head of Marketing. In addition to marketing, she will also focus on developing the Swedish market. Bactiguard is in a rapid expansion phase. Building strong marketing and sales capabilities to support our distributors across the world and develop direct...
Bactiguard establishes market presence in Portugal by entering an exclusive distribution agreement with Socime Medical Ltd, covering all products in the Bactiguard infection protection portfolio. Expanding our geographical footprint in Europe is an important part of Bactiguard’s strategy. By entering the Portuguese market we take an important...
Second quarter (April-June 2014) Revenues amounted to SEK 31.2 (22.1) million, an increase of 41% over the corresponding period last year EBITDA, excluding costs related to the IPO, amounted to SEK 5.2 (3.8) million, an increase of 36% Net profit for the quarter amounted to SEK -44.1 (-13.8) million, corresponding to SEK -2.04 (-0.69) per share,...
Bactiguard Holding AB publishes the interim report for the second quarter 2014 on August 15 at 08:00 CET. In connection with this, a telephone conference for analysts and media will be held at 10:00 CET on August 15. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Swedbank AB (publ) (”Swedbank”) has exercised the possibility to, in connection with the initial public offering (“IPO”) of Bactiguard Holding AB (publ) (“Bactiguard” or the”Company”), exercise price stabilization...
Bactiguard is expanding its business, with focus on Europe, the Middle East, Asia, South America and Southern Africa. The recruitment of Erik Düring as Regional Sales Director Europe is an important step in strengthening the sales and marketing organization, which supports the company’s distributors and develops the markets where Bactiguard...
Bactiguard establishes market presence in Southern Africa and has entered into exclusive distribution agreements, covering seven sub-Saharan countries and Bactiguard’s complete portfolio of solutions for infection control. An initial order for Foley catheters has already been shipped to Zambia. The order is for Foley catheters, primarily...
Bactiguard's proven and patented technology is the company's most important asset. Following articles in the Swedish newspaper Svenska Dagbladet, Bactiguard wishes to clarify some important facts. An article was today published in Svenska Dagbladet newspaper featuring Bactiguard's technology. Since the article does not give a fair picture, the...
In June 2014 the number of shares and votes in Bactiguard has increased by 12,786,373 Class B shares and the same number of votes. As earlier announced, the change in the number of shares and votes is a result of the new issues made in relation to the offer to acquire Class B shares in Bactiguard in connection with the listing of the company's...
A recently published clinical study* from the United States, concludes that Bactiguard coated Foley catheters significantly reduce symptomatic catheter associated urinary tract infections (CAUTI) and use of antibiotics. A 47-58 percent reduction of CAUTI and a 60 percent relative reduction of antibiotic use were recorded. This non-randomized...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Bactiguard Holding AB (publ) (“Bactiguard” or “The Company”) hereby announces the outcome of the offer to acquire shares in Bactiguard and listing on NASDAQ OMX Stockholm (“the Offer”). Interest in the Offer has been...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The board of directors of Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) and the Company’s principal owners, Thomas von Koch through Bactiguard B.V. and Christian Kinch through KK Invest AB, (”Principal...
At an expert panel session on 4 June 2014, the Chinese Center for Medical Device Evaluation (CMDE) informed that it will approve Bactiguard’s BIP Foley catheters. This is a major step en route towards final regulatory approval and commencement of sales in mainland China.The most important step in achieving regulatory approval for...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The information regarding the total nominal amount of bonds set-off for shares, which was communicated by Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) through press release titled “Set-off issue for...
Professor Kenneth Chien becomes Scientific Advisor to Bactiguard and will also lead the company’s Scientific Board. Professor Chien is an internationally recognized leader and pioneer in cardiovascular science. In 2013, he was recruited to Karolinska Institutet from Harvard University, USA. "Hospital Acquired infections are an increasing...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. On 23 May, 2014 Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) announced that holders of the Company’s bonds would be offered* the option to offset their bonds against Bactiguard shares....
Bactiguard’s BIP Foley Catheters in latex and silicone have been approved for new patient groups. The approval* includes patients who need suprapubic catheterization and long term usage. “Bactiguard’s growth strategy includes adding new devices and new applications to our product portfolio. The approval of our BIP Foley Catheters...
Bactiguard and MAQUET Critical Care AB (MAQUET), a division of the Getinge Group, enter a collaboration to develop Bactiguard®-coated catheters for patients in intensive care.Bactiguard’s strategy includes expanding its licensing business. MAQUET’s intention is to expand its portfolio of advanced monitoring solutions. Therefore,...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. In a press release issued today, the Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard” or “the Company”) confirmed its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm....
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. The Board of Directors of Bactiguard Holding AB (publ) (“Bactiguard”) confirms its intention to proceed with an IPO of Bactiguard on NASDAQ OMX Stockholm. Subject to necessary decisions being taken, receipt of NASDAQ OMX...
Bactiguard has signed an exclusive distribution agreement with Promedon, which allows the company to sell Bactiguard’s complete portfolio of medical devices in Argentina, Brazil, Chile and Mexico. Through this partnership, Bactiguard expands its market presence to 41 countries worldwide. Swedish medtech company Bactiguard has entered into an...
Swedish medical device company Bactiguard has signed Azaris Medical Equipment LLC in Ukraine to represent the company. Azaris Medical Equipment will be introducing Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. Bactiguard is present in over 35 countries worldwide and recently...
Swedish medical device company Bactiguard has been exhibiting at the health care exhibition Arab Health in Dubai since 2008. This year will be the 7th time the company is present at the exhibition. Arab Health plays a crucial role for not just health care in the Middle East-region, but also in a global perspective and makes an excellent arena for...
Swedish medtech company Bactiguard has signed Acucare Systems in Malaysia to represent the company in the Malaysian market. Acucare Systems will now be introducing Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. A few months ago Bactiguard proudly announced that they signed...
Swedish medtech company Bactiguard has signed SC. Alpha Medical SRL. for the Romanian market. Alpha Medical will now be introducing Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. Last week Bactiguard proudly announced that they signed distributors in Poland, Azerbaijan,...
Bactiguard is now entering the Polish and Slovenian markets after signing two new distributor agreements in Poland with Atmed, and in Slovenia with Farcom IZOLA. Earlier this week, Bactiguard announced that Azerbaijan, Kazakhstan and Uzbekistan are three new countries that now have access to Bactiguard’s unique technology. Christian Kinch, CEO...
The Swedish medtech company Bactiguard has signed distributor agreements for three new countries Azerbaijan, Kazakhstan and Uzbekistan. In May 2013 the Company Allmed Group became Bactiguard’s representative in Pakistan and that successful cooperation has now led to that Allmed Group will be introducing the Bactiguard Infection Protection...
The most important step in achieving regulatory approval for Bactiguard’s BIP Foley catheters on the Indian market has been accomplished. The Medical Device Advisory Committee has reviewed the Bactiguard file and recommended approval of BIP Foley catheters in India. CEO of Bactiguard, Christian Kinch: ” This approval is a milestone for...
Bactiguard has signed a Letter of Intent, LoI, with University Teaching Hospital, UTH, in Lusaka. UTH is the largest hospital in Zambia with 1600 hospital beds. Last week the LoI was signed in Lusaka and UTH plan to implement a Bactiguard Infection Protection Program during the fall of 2013. Zambia like most countries in Africa, face major...
During the past weeks the medtech company Bactiguard has signed distributor agreements for Ecuador, Turkey, Bosnia and Herzegovina, Egypt and Libya. Last week two more countries could be added to that list, Oman and Pakistan. The company Allmed Group will represent Bactiguard in these countries. CEO of Bactiguard, Christian Kinch, is very happy...
The Swedish medtech company Bactiguard has signed an exclusivity agreement with Tecnolab Cia Ltda. Guayaquil to represent the complete Bactiguard portfolio for infection control, including urinary, intravenous and respiratory catheters in Ecuador. This is a break through in South America for Bactiguard who already is present in over 25 countries...
Bactiguard has signed an exclusivity agreement with Proma doo Sarajevo, one of the strongest established medical suppliers in Bosnia. Proma doo Sarajevo will sell Bactiguard´s complete portfolio for infection control, including urinary, intravenous and respiratory catheters. “Bactiguard is very proud to be able to enter the Bosnian market. The...
Bactiguard has signed an exclusivity agreement with Capa Medikal, one of the strongest established medical suppliers in Turkey. Capa Medikal will sell Bactiguard´s complete infection protection portfolio, including urinary, intravenous and respiratory catheters. Mr. Zeki Avsar, General Manager, Capa Medikal: “Partnering with Bactiguard AB will...
That quote comes from the Swedish Prime Minister Fredrik Reinfeldt who is the keynote speaker at the 3rd World Youth and Child Forum, WYCF at the Royal Castle in Stockholm. An event hosted by the King and Queen of Sweden, today the 22 of March 2013. Bactiguard CEO, Christian Kinch and Vice President Linda Nyberg is attending the WYCF. A forum...
The Swedish Medtech company Bactiguard has made its full portfolio of infection protection products available in Middle East markets. In addition to the BIP Foley Catheters that are already available, Bactiguard´s BIP Endotracheal Tube and BIP Central Venous Catheter will now be introduced. The new products will be sold through Gulf Medical...
Today Bactiguard proudly announce that they have received the market authorisation by the Mexican health authority COFEPRIS. This means that Bactiguard now can enter and commercialize the BIP Foley Catheter product in Mexico. The distribution partner in Mexico; Grupo Comercial y de Servicios Del Valle (Cervantes group) will now work together with...
Bactiguard® is attending Arab Health the 28th to the 31st of January in order to present our unique solution to infection control and to introduce two new solutions within the Bactiguard Infection Protection (BIP) portfolio, the BIP Central Venous Catheter and BIP Endotracheal Tube. Arab Health is the largest healthcare exhibition and congress in...
Stockholm, Moscow January 2013. The Swedish medtech company Bactiguard has signed an exclusive co-operation with Intermedservice, IMS, one of the largest healthcare distributors in Russia with a turnover of more than €300 million. Intermedservice is present in Russia and the whole CIS region. IMS has now the exclusivity to sell the entire line...
The Swedish MedTech company Bactiguard is launching two new products for infection control at the Abu Dhabi Medical Congress The Abu Dhabi Medical Congress is the region’s fastest-growing healthcare event. Patient Safety is one of the key focus areas during this congress and Bactiguard is very proud to be a Platinum Sponsor to this event....
In an attempt to prevent Hospital Acquired Infections, Bactiguard donates 25 000 catheters to Egypt. Read more about the donation at Embassy of Sweden, Cairo >
The Swedish medtech company, Bactiguard has donated 50,000 catheters, valued at 1,000,000 U.S. dollars, and delivered them directly to the Libyan minister of health during a Swedish delegation held in Tripoli last week. Christian Kinch, the CEO and owner of Bactiguard, was personally present in Benghazi and Tripoli, to visit the hospitals which...
Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India with a global sales of 1,5 Billion US dollar (2010). Cadila Pharmaceuticals will sell the entire line of Bactiguard´s products throughout India. The Indian medical device market is currently worth approximately...
The Swedish medical technology company, Bactiguard has increased its market this past fall with China and South Korea and the expansion continues. The corporate bond that was issued to the public is now oversubscribed, as their ambition to raise between SEK 400 million and SEK 450 million was met. The reason for this is, according to Christian...
The Swedish medtech company Bactiguard has now entered into the market of yet another country, South Korea. On December 8th, one of the company´s most important and successful products, the BIP Foley Catheter, was approved in Korea. The BIP Foley Catheter has already been used by more than 110 million patients worldwide. The potential market in...
Coating the surface of an implant or a medical device with noble metals designed to have a surface-nanostructure may reduce the risk of rejection. The researchers can now explain why: the nanostructure fools the innate immune system. The results are presented in the International Journal of Nanomedicine and the project is a collaboration between...
On November 22, Bactiguard participated as co-organizer in the “Sweden-China Infection Control Seminar” hosted by the Swedish Embassy and the Swedish Trade Council in Beijing. The seminar was opened by Sweden’s Ambassador to China, Mr. Lars Fredén followed by four key note speakers talking about the threat of antibiotic resistance and the...
Bactiguard AB has signed a contract with The Innovation Center at Karolinska University Hospital in Huddinge, Sweden, for collaboration in the field of Life Science, with focus on hospital related infections and in other related care processes. Faults in hospital care claim approximately 3,000 lives annually in Sweden, alone. Care acquired...
Bactiguard has signed an exclusive agreement with the Chinese Pharmaceutical distributor, Jian An. The amount of 40 million Swedish kronor has been paid for the exclusive rights to sell the entire line of Bactiguard´s products throughout China. At the signing of the agreement, The Jian An company placed its first order of 70 000 Bactiguard...
Bactiguard has appointed Ewa Ställdal as Senior Advisor with start in April 2009. Ewa Ställdal, 59, is the Executive Director of the Swedish Foundation for Health Care Sciences and Allergy Research (the Vårdal Foundation), founded by the Swedish Parliament 1994. Ewa Ställdal worked as senior advisor in matters regarding medical education and...
Yesterday, Bactiguard was presented with the Swecare Export Award by the Minister for Health and Social Affairs, Göran Hägglund. The decisive factor for the jury was Bactiguard’s creative development of export opportunities. - Fantastic! Things are going extraordinarily well for Bactiguard just now and, with Swecare’s assistance, we have...
At 10am tomorrow, on Wednesday 1 October, Minister for Health and Social Affairs, Göran Hägglund, is visiting medical technology company Bactiguard’s production facility in Småland. Bactiguard’s technology contributes towards solving the problem of hospital acquired infections and could save the lives of at least 100 patients a year in...